Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.